D001749DisordersC04.588.945.947.960C12.758.820.968C12.777.829.813C13.351.937.820.945C13.351.968.829.7071093760.735282Urinary Bladder Neoplasmsplugins:TwitterTwitterprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson9.740540.0017693109research area of0.9905560.00531021413subject area forPiyushAgarwalPiyush Agarwal41.7886000000000087.598699999999993821Agarwal, PiyushProfessorMedicine-Hematology and OncologyTedSkolarusTed Skolarus41.7886000000000087.598699999999994249Skolarus, TedProfessorRandySweisMD37422371Kates M, Chu X, Hahn N, Pietzak E, Smith A, Shevrin DH, Crispen P, Williams SB, Daneshmand S, Packiam VT, Porten S, Westerman ME, Wagner LI, Carducci MEuropean urology focusBackground and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). Eur Urol Focus. 2023 07; 9(4):561-563.Eur Urol Focus2023-07-06T00:00:002023Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).37442672Dahl DM, Karrison TG, Michaelson MD, Pham HT, Wu CL, Swanson GP, Shipley WU, Vuky J, Lee RJ, Zietman AL, Souhami L, Chang BK, Deming RL, Ellerton JA, Sandler HM, Rodgers JP, Feng FY, Efstathiou JAEuropean urology oncologyLong-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation. Eur Urol Oncol. 2024 Feb; 7(1):83-90.Eur Urol Oncol2023-07-11T00:00:002023Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.MedicinePathologyUniversity of ChicagoGladell P.PanerGladell P. Paner41.78927490000000-87.60125000000000146Paner, Gladell P.ProfessorWalter M.StadlerWalter M. Stadler41.78927490000000-87.601250000000001904Stadler, Walter M.Professor38101433Grande E, Arranz JÁ, De Santis M, Bamias A, Kikuchi E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, O'Donnell PH, Kalebasty AR, Ye D, Mariathasan S, Bene-Tchaleu F, Bernhard S, Lee C, Davis ID, Galsky MDThe Lancet. OncologyAtezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 2024 Jan; 25(1):29-45.Lancet Oncol2023-12-12T00:00:002023Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.38228414Lynch C, Sweis RF, Modi P, Agarwal PK, Szmulewitz RZ, Stadler WM, O'Donnell PH, Liauw SL, Pitroda SPClinical genitourinary cancerBladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 Apr; 22(2):476-482.e1.Clin Genitourin Cancer2024-01-09T00:00:002024Bladder-Preserving Trimodality Therapy With Capecitabine.38323607Reis H, Paner GPAdvances in anatomic pathologyGlandular Lesions of the Urinary Bladder: Diagnostic and Molecular Updates. Adv Anat Pathol. 2024 Mar 01; 31(2):88-95.Adv Anat Pathol2024-02-07T00:00:002024Glandular Lesions of the Urinary Bladder: Diagnostic and Molecular Updates.true1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorSurgery-UrologyRandySweisxXF+DqgGOfnamXNnYUHhvWD+6g==Randy Sweis0.000000000000000.000000000000003318Sweis, RandyAssistant Professor